In a report released on December 15, Sam Slutsky from LifeSci Capital maintained a Hold rating on Third Harmonic Bio, Inc. (THRD – Research Report). The company’s shares opened today at $4.16.
Slutsky covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Third Harmonic Bio, Inc., and Celldex. According to TipRanks, Slutsky has an average return of 15.7% and a 44.34% success rate on recommended stocks.
Third Harmonic Bio, Inc. has an analyst consensus of Hold, with a price target consensus of $4.30, representing a 3.37% upside. In a report released on December 15, Jefferies also downgraded the stock to a Hold with a $3.60 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.60 and a one-year low of $3.99. Currently, Third Harmonic Bio, Inc. has an average volume of 276.4K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of THRD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Read More on THRD:
- Third Harmonic Bio downgraded to Hold from Buy at Jefferies
- Third Harmonic Bio downgraded to Market Perform at LifeSci Capital
- Morgan Stanley downgrades Third Harmonic after ‘disappointing’ discontinuation
- Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley
- Third Harmonic ‘further behind’ Celldex after discontinuation, says Guggenheim
